Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes

This publication has 207 references indexed in Scilit:

• Vitamin D and Immune Function
  Nutrients, 2013
• Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor
  PLOS ONE, 2013
• Vitamin D and Bone
  Current Osteoporosis Reports, 2012
• Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice
  American Journal of Physiology-Endocrinology and Metabolism, 2011
• Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study
  Diabetes, 2010
• Sitagliptin (MK0431) Inhibition of Dipeptidyl Peptidase IV Decreases Nonobese Diabetic Mouse CD4+ T-Cell Migration Through Incretin-Dependent and -Independent Pathways
  Diabetes, 2010
• Vitamin D Status Is Positively Correlated with Regulatory T Cell Function in Patients with Multiple Sclerosis
  PLOS ONE, 2009
• Convergence of IL-1β and VDR Activation Pathways in Human TLR2/1-Induced Antimicrobial Responses
  PLOS ONE, 2009
• Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation
  Diabetes, 2009
• DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27
  Nature Immunology, 2007